Article Text

Download PDFPDF
Refractory adult onset Still’s disease successfully treated with anakinra
  1. F M Vasques Godinho,
  2. M J Parreira Santos,
  3. J Canas da Silva
  1. Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal
  1. Correspondence to:
    Dr F M Vasques Godinho
    Av Prof Torrado da Silva, Hospital Garcia de Orta, Almada, Portugal;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Proinflammatory cytokines like tumour necrosis factor α (TNFα), interleukin (IL) 6, IL18, and IL1 have been implicated in the pathogenesis of several chronic rheumatic inflammatory diseases, including juvenile idiopathic arthritis and adult onset Still’s disease (AOSD).1–,5 The treatment of these diseases includes non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and, in resistant cases, methotrexate (MTX), cyclophosphamide, sulfasalazine, and ciclosporin A6–,8 have been used. Over the past years, several cases of successful treatment with infliximab and etanercept in AOSD, refractory to conventional drugs, have been published.8,9


We report a favourable response to anakinra in a patient unresponsive to several disease modifying antirheumatic drugs (DMARDs) and …

View Full Text